{"id":1854,"date":"2026-01-09T13:07:32","date_gmt":"2026-01-09T13:07:32","guid":{"rendered":"https:\/\/admarebio.com\/news-events\/news-insights\/"},"modified":"2026-06-26T13:07:32","modified_gmt":"2026-06-26T13:07:32","slug":"find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration","status":"publish","type":"post","link":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\/","title":{"rendered":"Find Therapeutics annonce une extension de son financement de s\u00e9rie A et la nomination du Dr Thierry Abribat \u00e0 la pr\u00e9sidence ex\u00e9cutive de son conseil d\u2019administration"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">La phase I \u00e9tant termin\u00e9e, Find avance vers la prochaine \u00e9tape clinique du tasron\u00e9tide, notamment un essai clinique de phase 1b avec imagerie TEP chez des personnes atteintes de scl\u00e9rose en plaques.<\/h4>\n\n\n\n<p>Une extension de financement de s\u00e9rie A de 10 millions de dollars canadiens a \u00e9t\u00e9 conclue, avec la participation d\u2019investisseurs existants : CTI Life Sciences, Investissement Qu\u00e9bec et adMare BioInnovations. Ce financement fait suite \u00e0 la r\u00e9ussite d\u2019un essai clinique de phase I men\u00e9 chez des sujets sains avec le tasron\u00e9tide, candidat m\u00e9dicament principal de Find, un peptide de premi\u00e8re classe ciblant le complexe r\u00e9cepteur NRP1\/Plexin-A1 afin de restaurer la remy\u00e9linisation naturelle. Les fonds serviront \u00e0 soutenir les activit\u00e9s de pr\u00e9paration \u00e0 la phase II, notamment un essai clinique de phase 1b avec imagerie TEP chez des personnes atteintes de scl\u00e9rose en plaques.<\/p>\n\n\n\n<p>Find Therapeutics annonce \u00e9galement la nomination du Dr Thierry Abribat au poste de pr\u00e9sident ex\u00e9cutif du conseil d\u2019administration, succ\u00e9dant \u00e0 Paul F. Truex, qui demeurera membre actif du conseil. Le Dr Abribat a rejoint le conseil d\u2019administration de Find plus t\u00f4t cette ann\u00e9e et est un dirigeant chevronn\u00e9 du secteur des biotechnologies, fort d\u2019une exp\u00e9rience reconnue dans la cr\u00e9ation et la r\u00e9ussite de plusieurs entreprises jusqu\u2019\u00e0 leur sortie. Dans le cadre de ses fonctions, il appuiera le pr\u00e9sident et chef de la direction par int\u00e9rim de Find Therapeutics, le Dr Fr\u00e9d\u00e9ric Lema\u00eetre Auger, dans la conduite de la strat\u00e9gie et des activit\u00e9s de l\u2019entreprise.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>Cette extension de la s\u00e9rie A t\u00e9moigne de la confiance continue de nos investisseurs envers la mission et les progr\u00e8s de Find. Gr\u00e2ce \u00e0 ce financement additionnel, nous sommes bien positionn\u00e9s pour faire progresser notre pipeline, notamment en r\u00e9alisant un essai TEP de phase 1b visant \u00e0 r\u00e9duire les risques et en atteignant la pr\u00e9paration \u00e0 la phase II. Nous sommes \u00e9galement heureux d\u2019accueillir Thierry \u00e0 titre de pr\u00e9sident ex\u00e9cutif et de continuer de b\u00e9n\u00e9ficier de l\u2019appui de Paul au conseil d\u2019administration. Leur exp\u00e9rience et leur vision strat\u00e9gique seront pr\u00e9cieuses alors que nous faisons progresser nos programmes et nous montrons pr\u00eats pour la prochaine \u00e9tape de croissance.Dr Fr\u00e9d\u00e9ric Lema\u00eetre Auger<\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>Je suis honor\u00e9 d\u2019assumer le r\u00f4le de pr\u00e9sident ex\u00e9cutif \u00e0 un moment aussi d\u00e9terminant pour Find Therapeutics. Son programme clinique principal, le tasron\u00e9tide, repose sur une science solide et les donn\u00e9es pr\u00e9cliniques soutiennent un profil diff\u00e9renci\u00e9. Notre \u00e9quipe est profond\u00e9ment engag\u00e9e \u00e0 offrir une approche th\u00e9rapeutique nouvelle et n\u00e9cessaire aux patients atteints de maladies d\u00e9my\u00e9linisantes. Je me r\u00e9jouis de travailler en \u00e9troite collaboration avec le conseil d\u2019administration et l\u2019\u00e9quipe de direction afin d\u2019accompagner l\u2019entreprise vers sa prochaine phase de croissance.Dr Thierry Abribat<\/p>\n<\/blockquote>\n\n\n\n<p><strong>\u00c0 propos du tasron\u00e9tide (anciennement FTX-101)<\/strong><\/p>\n\n\n\n<p>Le candidat m\u00e9dicament clinique de Find, le tasron\u00e9tide, est un agent remy\u00e9linisant de premi\u00e8re classe destin\u00e9 au traitement de la neuropathie optique chronique et de la scl\u00e9rose en plaques (SEP). Le tasron\u00e9tide est un peptide th\u00e9rapeutique qui cible le domaine transmembranaire du complexe r\u00e9cepteur NRP1\/Plexin-A1. Surexprim\u00e9 dans le cerveau des personnes atteintes de SEP, ce complexe a \u00e9t\u00e9 d\u00e9montr\u00e9 comme inhibant \u00e0 la fois la migration et la diff\u00e9renciation des cellules prog\u00e9nitrices d\u2019oligodendrocytes en oligodendrocytes my\u00e9linisants. Des donn\u00e9es pr\u00e9cliniques convaincantes obtenues avec le tasron\u00e9tide dans des mod\u00e8les de d\u00e9my\u00e9linisation d\u00e9montrent une neuroprotection et une activit\u00e9 robuste de r\u00e9paration de la my\u00e9line. Des donn\u00e9es cliniques r\u00e9centes de phase I montrent que le tasron\u00e9tide est s\u00fbr et bien tol\u00e9r\u00e9.<\/p>\n\n\n\n<p><strong>\u00c0 propos de Find Therapeutics<\/strong><\/p>\n\n\n\n<p>Find Therapeutics est une soci\u00e9t\u00e9 biopharmaceutique au stade clinique d\u00e9di\u00e9e au d\u00e9veloppement de th\u00e9rapies de nouvelle g\u00e9n\u00e9ration pour traiter les maladies d\u00e9my\u00e9linisantes, telles que la neuropathie optique chronique et la scl\u00e9rose en plaques. La soci\u00e9t\u00e9 s\u2019appuie sur une technologie et un savoir-faire issus du fondateur scientifique, le Dr Dominique Bagnard, professeur \u00e0 l\u2019Universit\u00e9 de Strasbourg, dans le cadre d\u2019une licence exclusive conclue avec SATT-Conectus. Visitez&nbsp;<a href=\"https:\/\/www.findtherapeutics.com\/\" rel=\"noreferrer noopener\" target=\"_blank\">findtherapeutics.com<\/a>&nbsp;pour en savoir plus sur Find Therapeutics.<\/p>\n\n\n\n<p><strong>\u00c9nonc\u00e9s prospectifs<\/strong><\/p>\n\n\n\n<p>Ce communiqu\u00e9 de presse contient des \u00e9nonc\u00e9s prospectifs concernant les plans et strat\u00e9gies de Find Therapeutics. Les r\u00e9sultats r\u00e9els pourraient diff\u00e9rer en raison de risques et d\u2019incertitudes. Find Therapeutics n\u2019assume aucune obligation de mettre \u00e0 jour ces \u00e9nonc\u00e9s, sauf dans la mesure requise par les lois applicables.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.findtherapeutics.com\/fr\/extension-du-financement-serie-a-et-mise-a-jour-du-ca\/\">&nbsp;Lire le communiqu\u00e9 original&nbsp;<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La phase I \u00e9tant termin\u00e9e, Find avance vers la prochaine \u00e9tape clinique du tasron\u00e9tide, notamment un essai clinique de phase 1b avec imagerie TEP chez des personnes atteintes de scl\u00e9rose [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":1925,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41],"tags":[],"company":[110],"class_list":["post-1854","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites-des-compagnies-du-portefeuille"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Find Therapeutics annonce une extension de son financement de s\u00e9rie A et la nomination du Dr Thierry Abribat \u00e0 la pr\u00e9sidence ex\u00e9cutive de son conseil d\u2019administration | adMare<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Find Therapeutics annonce une extension de son financement de s\u00e9rie A et la nomination du Dr Thierry Abribat \u00e0 la pr\u00e9sidence ex\u00e9cutive de son conseil d\u2019administration | adMare\" \/>\n<meta property=\"og:description\" content=\"La phase I \u00e9tant termin\u00e9e, Find avance vers la prochaine \u00e9tape clinique du tasron\u00e9tide, notamment un essai clinique de phase 1b avec imagerie TEP chez des personnes atteintes de scl\u00e9rose [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-09T13:07:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-26T13:07:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1199\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Earnscliffe Strategies\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Earnscliffe Strategies\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\\\/\"},\"author\":{\"name\":\"Earnscliffe Strategies\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\"},\"headline\":\"Find Therapeutics annonce une extension de son financement de s\u00e9rie A et la nomination du Dr Thierry Abribat \u00e0 la pr\u00e9sidence ex\u00e9cutive de son conseil d\u2019administration\",\"datePublished\":\"2026-01-09T13:07:32+00:00\",\"dateModified\":\"2026-06-26T13:07:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\\\/\"},\"wordCount\":834,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/find-therapeutics-fr-1744304415.png\",\"articleSection\":[\"Actualit\u00e9s des compagnies du portefeuille\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\\\/\",\"name\":\"Find Therapeutics annonce une extension de son financement de s\u00e9rie A et la nomination du Dr Thierry Abribat \u00e0 la pr\u00e9sidence ex\u00e9cutive de son conseil d\u2019administration | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/find-therapeutics-fr-1744304415.png\",\"datePublished\":\"2026-01-09T13:07:32+00:00\",\"dateModified\":\"2026-06-26T13:07:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/find-therapeutics-fr-1744304415.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/find-therapeutics-fr-1744304415.png\",\"width\":1199,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &#038; Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News &#038; Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Find Therapeutics annonce une extension de son financement de s\u00e9rie A et la nomination du Dr Thierry Abribat \u00e0 la pr\u00e9sidence ex\u00e9cutive de son conseil d\u2019administration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\",\"name\":\"Earnscliffe Strategies\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Find Therapeutics annonce une extension de son financement de s\u00e9rie A et la nomination du Dr Thierry Abribat \u00e0 la pr\u00e9sidence ex\u00e9cutive de son conseil d\u2019administration | adMare","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Find Therapeutics annonce une extension de son financement de s\u00e9rie A et la nomination du Dr Thierry Abribat \u00e0 la pr\u00e9sidence ex\u00e9cutive de son conseil d\u2019administration | adMare","og_description":"La phase I \u00e9tant termin\u00e9e, Find avance vers la prochaine \u00e9tape clinique du tasron\u00e9tide, notamment un essai clinique de phase 1b avec imagerie TEP chez des personnes atteintes de scl\u00e9rose [&hellip;]","og_url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\/","og_site_name":"adMare","article_published_time":"2026-01-09T13:07:32+00:00","article_modified_time":"2026-06-26T13:07:32+00:00","og_image":[{"width":1199,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png","type":"image\/png"}],"author":"Earnscliffe Strategies","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Earnscliffe Strategies","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\/"},"author":{"name":"Earnscliffe Strategies","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da"},"headline":"Find Therapeutics annonce une extension de son financement de s\u00e9rie A et la nomination du Dr Thierry Abribat \u00e0 la pr\u00e9sidence ex\u00e9cutive de son conseil d\u2019administration","datePublished":"2026-01-09T13:07:32+00:00","dateModified":"2026-06-26T13:07:32+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\/"},"wordCount":834,"publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png","articleSection":["Actualit\u00e9s des compagnies du portefeuille"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\/","url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\/","name":"Find Therapeutics annonce une extension de son financement de s\u00e9rie A et la nomination du Dr Thierry Abribat \u00e0 la pr\u00e9sidence ex\u00e9cutive de son conseil d\u2019administration | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png","datePublished":"2026-01-09T13:07:32+00:00","dateModified":"2026-06-26T13:07:32+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png","width":1199,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/find-therapeutics-annonce-une-extension-de-son-financement-de-serie-a-et-la-nomination-du-dr-thierry-abribat-a-la-presidence-executive-de-son-conseil-dadministration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/fr\/"},{"@type":"ListItem","position":2,"name":"News &#038; Events","item":"https:\/\/admarebio.com\/fr\/news-events\/"},{"@type":"ListItem","position":3,"name":"News &#038; Insights","item":"https:\/\/admarebio.com\/fr\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"Find Therapeutics annonce une extension de son financement de s\u00e9rie A et la nomination du Dr Thierry Abribat \u00e0 la pr\u00e9sidence ex\u00e9cutive de son conseil d\u2019administration"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/fr\/#website","url":"https:\/\/admarebio.com\/fr\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/fr\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da","name":"Earnscliffe Strategies","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1854","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/comments?post=1854"}],"version-history":[{"count":1,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1854\/revisions"}],"predecessor-version":[{"id":1855,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1854\/revisions\/1855"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media\/1925"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media?parent=1854"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/categories?post=1854"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/tags?post=1854"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/company?post=1854"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}